The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAbbott Laboratories continues to navigate market shifts as UBS analysts maintain a $115.00 price target despite a recent revision in long-term guidance. Although Abbott's Q1 2026 earnings beat initial estimates, analysts have slashed the company's full-year 2026 earnings outlook below previous expectations. The company remains focused on integrating its $23 billion acquisition of Exact Sciences, supported by a 13.2% growth in its Medical Devices segment. Meanwhile, Bank of New York Mellon (BK) reported first-quarter 2026 financial results that exceeded market expectations, signaling strength in the broader financial services sector. Investors are weighing Abbott's strong divisional performance against the lowered long-term earnings forecasts.